Skip to main content
TiumBio Co., Ltd. logo

TiumBio Co., Ltd. — Investor Relations & Filings

Ticker · 321550 ISIN · KR7321550006 KO Professional, scientific and technical activities
Open in API
Filings indexed 296 across all filing types
Latest filing 2021-11-30 Director's Dealing
Country KR South Korea
Listing KO 321550

About TiumBio Co., Ltd.

http://www.tiumbio.com/en/

TiumBio is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapeutics for rare and incurable diseases. The company's pipeline targets conditions with high unmet medical needs, including fibrotic diseases, cancer, and rare hematological disorders. Its lead assets include Merigolix (TU2670), an oral GnRH antagonist in clinical development for endometriosis and uterine fibroids, and TU7710, a long-acting recombinant activated factor VII for hemophilia. TiumBio also develops small molecule antagonists targeting the TGF-β signaling pathway for applications in oncology and fibrosis. The company advances its programs through clinical development and strategic global partnerships.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Financial Supervisory Service (Korea). This document details the changes in share ownership by a company director (Jung Jinwoo) of TiumBio. This falls under the category of 'Director's Dealing' (DIRS), which covers insider trades and changes in shareholdings by company executives.
2021-11-30 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean financial authorities. This type of filing is a standard regulatory disclosure for insider trading or changes in share ownership by company directors and executives. Based on the provided definitions, this falls under 'Director's Dealing' (DIRS).
2021-11-30 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and is a '정정신고' (Amendment Report). It details changes to stock option grants, including the number of recipients and the number of shares, filed with the Financial Supervisory Service/Korea Exchange. Since it is a specific regulatory disclosure regarding capital structure and employee compensation instruments that does not fit into the other categories like 'SHA' (which is for new share issues/capital changes) or 'DIRS' (which is for director dealings), it falls under the general regulatory filing category.
2021-11-23 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and is a correction (정정신고) to a previous filing. It details changes to stock option grants, including the number of recipients and the number of shares granted. In the context of Korean regulatory filings (DART), this type of disclosure regarding stock options and capital changes falls under general regulatory announcements or specific share-related disclosures. Since it is a formal regulatory filing regarding the modification of stock-based compensation and capital structure, it is best classified as a Regulatory Filing (RNS).
2021-11-23 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on the Granting of Stock Options). It details the issuance of stock options to specific employees and executives, including the number of shares, exercise price, and vesting conditions. This type of disclosure regarding capital structure changes and equity-based compensation is classified as a 'Share Issue/Capital Change' (SHA) filing in the provided taxonomy.
2021-11-23 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and specifically functions as a '정정신고' (Amendment Report) to a previously submitted filing. It details changes to the number of recipients and the total number of shares granted due to employee resignations. Since this is a specific regulatory disclosure regarding capital structure and equity compensation, and it does not fit into the other specific categories like 'Director's Dealing' (which is for personal trades) or 'Share Issue' (which is for new capital issuance), it is classified as a general regulatory filing.
2021-11-23 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.